COVID-19 Monoclonal Antibody Assessment & Administration

Activity Preview

The U.S. Food and Drug Administration has issued several Emergency Use Authorizations for the use of anti-SARS-CoV-2 monoclonal antibodies - bamlanivimab/etesevimab, casirivimab/imdevimab, and sotrovimab.  With the Department of Health and Human Services' 9th Amendment to the Public Readiness and Emergency Preparedness (PREP) Act, licensed pharmacists are now authorized to both order and administer monoclonal antibodies as COVID-19 therapeutics. We’ll review the clinical evaluation of indications and contraindications for COVID-19 therapeutics, adverse events, as well as and product-specific requirements or considerations related to FDA approval, authorization, clearance or licensing of COVID-19 therapeutics. This training program is designed to fully satisfy the requirements of the PREP Act by supplementing APhA's Pharmacy-based Immunization Delivery certificate training program. 

Target Audience: Pharmacists
CEUs: 0.10 - 1 contact hour of CPE credit
ACPE UAN(s): 0202-0000-21-355-H06-P
Activity type: Application-based
Expiration date: September 16, 2024 - No credit can be earned after this date

Learning Objectives

At the completion of this activity, pharmacists will be able to:

  1. Describe the mechanism of action of anti-SARS-CoV-2 monoclonal antibodies.
  2. Discuss eligibility requirements for use of monoclonal antibodies as outlined by the current US Food and Drug Administration (FDA) Emergency Use Authorizations (EUA)
  3. Review the efficacy of monoclonal antibodies in the treatment and prevention of COVID-19
  4. Discuss potential adverse events of monoclonal antibodies administration
  5. Review key counseling points for patients receiving anti-SARS-CoV-2 monoclonal antibodies

Accreditation Information 

APhA Logo
The American Pharmacists Association is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education (CPE). 
To obtain credit for this learning activity, the following criteria must be met:
  • A valid and updated APhA account including the following information:
    • NABP e-Profile ID and PIN
    • Florida Pharmacist / Pharmacist Technician license number (only applicable to Florida Pharmacists and Pharmacy Technicians)
    • Access your APhA account here to verify the above information is included https://ebusiness.pharmacist.com/PersonifyEbusiness/My-Account
  • Completion of this activity
    • Activity will need to be viewed in full
    • Assessment successfully completed with a grade of 70% or better
    • Course evaluation completed

    Within 24 hours of full completion of activity and claiming credit your CPE transcript will be on your CPE Monitor account.

    APhA continuing pharmacy education policy provides learners with two opportunities to successfully complete the continuing pharmacy education assessment. Please note that you will not be permitted to submit the assessment a third time. The current policy of the APhA Education Department is not to release the correct answers to any of our CPE tests. This policy is intended to maintain the integrity of the CPE activity and the assessment.

Development

Monoclonal Antibodies: Assessment and Administration of COVID-19 Therapy is an education activity for pharmacists developed by the American Pharmacists Association.© 2021 American Pharmacists Association

Disclosures

APhA’s editorial staff declare no conflicts of interest or financial interests in any product or service mentioned in this activity, including grants, employment, gifts, stock holdings, and honoraria. For a complete list of APhA staff disclosures, please visit the APhA website at www.pharmacist.com/apha-disclosures.  

Activity Fee

There is no fee for APhA Members or non-members. 

System Requirements

Computer and Internet access is required to complete this activity.  Please visit our website to view the Technology System Requirements to have a positive learning experience.

Credit Information

Activity Number Credit Amount Accreditation Period
ACPE# 0202-0000-21-355-H06-P 0.1 CEUs September 16, 2021 - September 16, 2024